<DOC>
	<DOCNO>NCT01476475</DOCNO>
	<brief_summary>Primary Objective : - The purpose study compare insulin glargine/ lixisenatide fix ratio combination ( FRC ) versus insulin glargine glycemic control 24 week , evaluate glycosylated hemoglobin ( HbA1c ) reduction type 2 diabetic participant treat metformin . Secondary Objectives : - To compare insulin glargine/lixisenatide FRC versus insulin glargine 24 week : - Glycemic control relation meal evaluate post-prandial plasma glucose glucose excursion standardize meal test ; - Percentage participant reach HbA1c &lt; 7 % ≤6.5 % ; - 7-point Self-Monitored Plasma Glucose ( SMPG ) profile ; - Body weight ; - Insulin glargine dose - Fasting Plasma Glucose ( FPG ) ; - Percentage participant require rescue therapy 24-week open label treatment period ; - To assess safety tolerability insulin glargine/lixisenatide FRC .</brief_summary>
	<brief_title>Efficacy Safety Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone Top Metformin Type 2 Diabetic Patients</brief_title>
	<detailed_description>Approximately 27 week include 24-week treatment period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Participants type 2 diabetes mellitus diagnose least 1 year . Metformin treatment stable dose least 1.5 g/day least 3 month prior screen . Exclusion criterion : Age &lt; legal age adulthood ( 18 year ) . Screening HbA1c &lt; 7 % &gt; 10 % . Screening FPG &gt; 250 mg/dL ( &gt; 13.9 mmol/L ) . Pregnancy lactation , woman childbearing potential effective contraceptive method . Type 1 diabetes mellitus . Treatment glucoselowering agent ( ) metformin period 3 month prior screen . Use insulin within last 6 month . Previous use insulin , except episode ( ) shortterm treatment ( ≤15 consecutive day ) due intercurrent illness . Amylase and/or lipase &gt; 3 time upper limit normal laboratory range ( ULN ) screening . Calcitonin ≥20 pg/ml ( 5.9 pmol/l ) screening . Alanine Transferase ( ALT ) &gt; 3 ULN screening . History unexplained pancreatitis , chronic pancreatitis , pancreatectomy . Personal immediate family history medullary thyroid cancer ( MTC ) genetic condition predisposes MTC ( e.g . multiple endocrine neoplasia syndrome ) . Uncontrolled inadequately control hypertension time screen rest supine systolic diastolic blood pressure &gt; 180 mmHg &gt; 110 mmHg , respectively . Within last 6 month prior screen : history heart failure require hospitalization , myocardial infarction , stroke . Planned coronary , carotid peripheral artery revascularisation procedure . Body Mass Index ( BMI ) ≤20 &gt; 40 kg/m^2 . Any previous treatment lixisenatide The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>